Enrollment opens in phase I study of LP-168 in relapsed or refractory B-cell malignancies Aug. 5, 2021
Phase IIb/III ALLEGRO trial of ritlecitinib in alopecia areata meets primary efficacy endpoint Aug. 4, 2021
RSS